421 filings
Page 9 of 22
6-K
vcour2
9 Aug 19
Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
8:00am
UPLOAD
2szjf3 zbhenvm
9 Aug 19
Letter from SEC
12:00am
CORRESP
marzq9nvp
8 Aug 19
Correspondence with SEC
12:00am
6-K
sbbei46rg ng
7 Aug 19
Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call
8:00am
F-3
lmcnrm hg6ahyf6p
7 Aug 19
Shelf registration (foreign)
12:00am
6-K
o4kyxhlv6mp2xufid57i
6 Aug 19
Notice of Annual and Special Meeting of Shareholders
12:00am
6-K
lype0 pnyx2
25 Jul 19
Current report (foreign)
3:56pm
EFFECT
np87wr8yyq0etw edd
18 Jul 19
Notice of effectiveness
12:15am
POS AM
vs32 i9mp6
15 Jul 19
Prospectus update (post-effective amendment)
5:15pm
6-K
u01 qtvghy
5 Jul 19
Current report (foreign)
9:00am
6-K
fncvc
26 Jun 19
Acasti Pharma Provides Fiscal 2019 Year-End Business Update
8:06am
6-K
hihg7dltm4ii oj6rd3
24 Jun 19
Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
9:01am
6-K
kr4f 478dnr3rhl
19 Jun 19
Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call
8:00am
6-K
bihzzi8szx1c0u1
4 Jun 19
Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
9:15am
6-K
la749j6y88gqh40p
21 May 19
Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
7:31am
6-K
ri6a1i40 yg
15 May 19
Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
7:56am
6-K
mkvev25
10 May 19
Current report (foreign)
10:05am
6-K
dk7b7 ba60wzkcj5t6
24 Apr 19
Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
8:35am
6-K
ma6 xuv9d
15 Apr 19
Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
9:15am